AstraZeneca plans Shanghai cell therapy and innovation hub
AstraZeneca will build a cell therapy base and innovation centre in Shanghai. The site will produce CAR-T treatments for China and other broader Asian markets.
Xurve View
洞察:
Xurve View
AstraZeneca PLC has announced plans to establish a cell therapy manufacturing and supply base alongside a new innovation center in Shanghai. This development positions the United Kingdom-based pharmaceutical giant as the first global drugmaker to develop end-to-end cell therapy capabilities within China. The facility will focus on the production and supply of CAR-T cell therapies, which modify a patient's immune cells to target and destroy cancer cells, serving both the local market and other regions across Asia.
